

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A preparation comprising:

- (1) (5Z, 7E) - (1R, 2R, 3R) -2- (3-hydroxypropoxy) - 9, 10-secocholesta-5, 7, 10(19)-triene-1, 3, 25-triol;
- (2) fat and oil; and
- (3) an antioxidant,

wherein the degradation of (5Z, 7E) - (1R, 2R, 3R) -2- (3-hydroxypropoxy) - 9, 10-secocholesta-5, 7, 10(19)-triene-1, 3, 25-triol into 6E- (1R, 2R, 3R) -2- (3-hydroxypropoxy) - 9, 10-secocholesta-5(10), 6, 8(9)-triene-1, 3, 25-triol and/or (5E, 7E) - (1R, 2R, 3R) -2- (3-hydroxypropoxy) - 9, 10-secocholesta-5, 7, 10(19)-triene-1, 3, 25-triol is suppressed.

Claims 2-4. (Cancelled)

5. (Currently Amended) The preparation according to claim 2 1, wherein the degradation product of (5Z, 7E) - (1R, 2R, 3R) -2- (3-hydroxypropoxy) - 9, 10-secocholesta-5, 7, 10(19)-triene-1, 3, 25-triol is 6E- (1R, 2R, 3R) -2- (3-hydroxypropoxy) - 9, 10-secocholesta-5(10), 6, 8(9)-triene-1, 3, 25-triol and (5E, 7E) - (1R, 2R, 3R) -2- (3-hydroxypropoxy) - 9, 10-secocholesta-5, 7, 10(19)-triene-1, 3, 25-triol.

6. (Currently Amended) The preparation according to ~~any one of claims 1 to 5~~, wherein the antioxidant is one member selected from dl- $\alpha$ -tocopherol, dibutylhydroxytoluene, butylhydroxyanisole, and propyl gallate.

7. (Currently Amended) The preparation according to ~~any one of claims claim 1, 5 to or 6~~, wherein the preparation is a soft capsule, hard capsule, or oily liquid preparation.

8. (Currently Amended) The preparation according to ~~any one of claims 1 to 7~~, wherein the preparation is a soft capsule.

9. (Currently Amended) The preparation according to ~~any one of claims 1, 5 to or 86~~, wherein the preparation comprises 0.000001 to 0.01% by weight of (5Z,7E)-(1R,2R,3R)-2-(3-hydroxypropoxy)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol relative to the fat and oil and 0.0001 to 12% by weight of the antioxidant relative to the fat and oil.

10. (Previously Presented) (5E,7E)-(1R,2R,3R)-2-(3-hydroxypropoxy)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol.

11. (New) Isolated (5E,7E)-(1R,2R,3R)-2-(3-hydroxypropoxy)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol.

12. (New) A method of suppressing the generation of the degradation products 6E-(1R,2R,3R)-2-(3-hydroxypropoxy)-9,10-secocholesta-5(10),6,8(9)-triene-1,3,25-triol and/or (5E,7E)-(1R,2R,3R)-2-(3-hydroxypropoxy)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol in a oily preparation comprising (5Z,7E)-(1R,2R,3R)-2-(3-hydroxypropoxy)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol, comprising adding an antioxidant to the preparation.

13. (New) The method of Claim 12, wherein the amount of each of the degradation products generated in the preparation after 12-month storage at room temperature under shading is suppressed to 1% or less.